Inactive Instrument

Other languages Context Therapeutics Inc.

Equities

US21077P1084

Real-time Estimate Cboe BZX Other stock markets 09:32:39 21/05/2024 pm IST			5-day change	1st Jan Change
2.025 ^USD	-84.42%		0.00%	0.00%

08/05	Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Context Therapeutics Announces FDA Clearance of IND Application for A Phase 1 Clinical Trial of CTIM-76	02/05
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers	01/04
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Context Therapeutics Inc. Amends its Collaboration and Licensing Agreement with Integral Molecular, Inc	06/03
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Context Therapeutics Inc. Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer	06/23/06
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers	09/23/09
Context Therapeutics Inc. Enrolls the First Patient in the Elona Study	04/23/04
Context TherapeuticsÂ® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer	08/22/08
Context Therapeutics Inc. Announces Research Collaboration and Licensing Agreement with Integral Molecular	29/22/29
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10
Context Therapeutics Extends Runway into First Quarter 2024	27/22/27
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12
Context Therapeutics and the Menarini Group Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Ona-XR and Elacestrant Combination	02/22/02
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	24/22/24
Context Therapeutics Inc. Announces Management Changes	06/22/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Context Therapeutics Inc.

Equities

US21077P1084

Other languages

Filters